The Center for Innovation and Free Enterprise supports the adoption of the Toomey Amendments (#1 and #6) to the Prescription Drug Pricing Reduction Act of 2019 (PDPRA). In its current form, the PDPRA sets an inflationary rebate penalty for Medicare Part D, undermining the free market success of the program. This penalty is nothing more than a restrictive government price control. Toomey Amendment #1 will strip those inflationary rebates from Part D and Toomey Amendment #6 will prohibit the International Pricing Index Model, a detrimental obstacle to Medicare Part B.
Tomorrow morning, the Prescription Drug Pricing Reduction Act of 2019 is set for a markup. It is imperative that both Toomey Amendments pass to protect the long-standing success of the Medicare Part D and Medicare Part B programs. We are proud to voice our support for these necessary amendments and urge congressional members to do the same in the form of co-sponsoring both Toomey Amendments to protect our free-market principles, oppose price controls, and ban the IPI Model.